GlassScriptPhysician profile
Matthew F Conigliari
NPI 1417958604
$9,105.32
in general payments reported to CMS, 2019-2025
62 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,585 · 2020: $1,034 · 2021: $1,438 · 2022: $1,319 · 2023: $1,159 · 2024: $1,424 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,729.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,465.51 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,214.26 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $848.58 | 2019-2024 | Austedo Xr, Austedo |
| Amgen INC. | $513.69 | 2019-2025 | Uplizna |
| Pfizer INC. | $401.48 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $275.21 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $261.65 | 2021-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $260.82 | 2019-2021 | |
| Lilly USA, LLC | $260.46 | 2019-2025 | Kisunla, Amyvid |
| Biogen, INC. | $246.29 | 2019-2024 | Leqembi |
| Ucb, INC. | $228.87 | 2019-2024 | Briviact |
| Emd Serono, INC. | $213.33 | 2019-2024 | Mavenclad |
| Tg Therapeutics, INC. | $206.58 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $175.22 | 2022 | |
| Lundbeck LLC | $154.33 | 2019-2025 | Vyepti, Rexulti |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Conigliari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.